Mohammadamin Asadirad, Pharm.D. MS. RPh’s Post

Coinhibition of topoisomerase 1 (TOP1) and bromodomain-containing protein 4 (BRD4) synergistically induces tumor regression. This synergistic effect of TOP1 + BRD4 inhibition is specific to cancer cells leaving normal cells unaffected, which is very interesting from safety and quality-of-life perspective. We have a strong interest from our research on chemotherapy induced mucositis. https://lnkd.in/dMweZ2QU

Didn't catch our posters at #AACR2024? 🤔 We presented a novel approach using patient-derived organoids and engineered T cell co-cultures for T cell drug development. Click on the link below to download the poster and learn: ✨How we developed an organoid-based co-culture system with engineered T cells ✨How we established a preclinical basket screen consisting of breast, colorectal, lung, head and neck, ovarian, and pancreatic organoids to help with our client's research needs ✨How organoid technology helped our client in making clinically informed decisions on selection of disease indication for their IO compound in solid tumors #Tcells #CART #engineeredTcells #organoids #TME #patientinthelab #cancer #immunotherapy

【Magnetic Field Emulations of Small Inhibitor RNA: Effects on Implanted GL261 Tumors in C57BL/6 Immune Competent Mice】 Full article: https://lnkd.in/gjSupUGW (Authored by Xavier A. Figueroa, et al., from EMulate Therapeutics Inc., USA.)   The flexibility of small inhibitor RNAs (siRNAs) technology and the proof-of-concept with epidermal growth factor receptor (EGFR) siRNA signal allows developing therapeutic signals against established clinical targets. This paper presents the results of digitally encoded signal mixtures (electromagnetic recordings of siRNA for cytotoxic T lymphocyte–associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1)) in reducing the tumor volume of implanted GL261 mouse-derived glioblastoma in immune-competent C57BL/6 mice. #Electromagnetic_Field #Emulation #Cancer #Tumor

🔬 Exploring Advances in Solid Tumour Diagnostics 🔬 Findings : Concomitant KRAS and PIK3CA mutations Notes: KRAS mutations are prevalent in approximately 45% of colon adenocarcinomas, making them a key focus in understanding tumour behaviour and therapy resistance (Porru et al., 2018). KRAS mutation status serves as a predictive biomarker for the efficacy of EGFR-targeted therapies. Tumours with KRAS mutations often show resistance to anti-EGFR antibody therapies, either alone or in combination with chemotherapy (Van Cutsem et al., 2016). Moreover, the presence of concomitant KRAS and PIK3CA mutations in colorectal cancer is linked to more aggressive disease features and poorer overall survival outcomes (Luo et al., 2020). These insights underline the importance of precise molecular diagnostics in tailoring effective treatment strategies for patients. #CancerResearch #Oncology #MolecularDiagnostics #KRAS #PIK3CA #ColorectalCancer #PrecisionMedicine#

Happy to share that the IDO1 inhibitor paper that I co-authored is finally published in Clinical Cancer Research. We got some interesting biomarker data. I am truly thankful to the amazing team, patients and their families. Purpose: To evaluate linrodostat mesylate, a selective, oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, combined with nivolumab ± ipilimumab in advanced solid tumors and hematologic malignancies. Conclusions: Linrodostat + nivolumab ± ipilimumab demonstrated a manageable safety profile. Kynurenine changes supported IDO1 pathway inhibition but did not correlate with response. A composite biomarker of low TDO2 expression plus high IFN-γ gene expression may predict response to linrodostat + nivolumab. #BMS_employee #CCR #IDO1

【Magnetic Field Emulations of Small Inhibitor RNA: Effects on Implanted GL261 Tumors in C57BL/6 Immune Competent Mice】 Full article: https://lnkd.in/g74jy-KG (Authored by Xavier A. Figueroa, et al., from EMulate Therapeutics Inc., USA.) The flexibility of small inhibitor RNAs (siRNAs) technology and the proof-of-concept with epidermal growth factor receptor (EGFR) siRNA signal allows developing therapeutic signals against established clinical targets. This paper presents the results of digitally encoded signal mixtures (electromagnetic recordings of siRNA for cytotoxic T lymphocyte–associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1)) in reducing the tumor volume of implanted GL261 mouse-derived glioblastoma in immune-competent C57BL/6 mice. #Electromagnetic_Field #Emulation #Cancer #Tumor

A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer https://lnkd.in/dJeUSvhy

Publication alert 10🎇📢🚨 Third one in a month......🚨🚨 We are excited to share that our review article entitled,"Unlocking the potential of Ibrutinib: A comprehensive review on its role in the multifaceted landscape of cancer Therapy" has been published in Process Biochemistry with an impact factor of 4.4. The present review elaborates the potential applications of Ibrutinib as an anti-cancer drug and present nanoformulation approaches. Many congratulations to the authors Sk Azizuddin MASEERA K. Nazeer Hasan 👏🎉🎇 Looking forward to many more collaboration 🎉 Link for accessing the article: https://lnkd.in/gyiYqm2T #reviewarticle #research #nanomedicine #cancerresearch

🚀 Presenting ADC Digest for March 2024!🔬💊 This week, the realm of Antibody Drug Conjugates (ADCs) is buzzing with phenomenal breakthroughs! Here's a glimpse: 🌍 Samsung collaborates with BrickBio to pioneer cutting-edge molecules and therapies using protein engineering for ADCs 🌍 Antengene embarks on Phase II Dose Expansion Study of Claudin 18.2 ADC ATG-022 in China and Australia, marking a significant stride in cancer treatment 🌍 Korean patients edge closer to affordable access to revolutionary cancer therapy, Enhertu. Stay tuned as we bring you more updates from the dynamic world of ADCs! #ADC #Antibodydrugconjugate #ADCnews #CIScientists #CompetitiveIntelligence #MedicalAdvancements #HealthcareRevolution Stay tuned for more updates in the world of ADCs!

A preprint on the colon selenoproteome accounts for GPXs and PRDX via thioredoxin reductase in effects as advised in my three recent commentaries (one in the preprint stage, noted in an earlier post). A recent preprint [DeAngelo SL, Dziechciarz S, Solanki S, Shin M, Zhao L, Balia A, El-Derany MO, Das NK, Castillo C, Bell HN, Paulo JA, Zhang Y, Rossiter NJ, McCulla EC, He J, Talukder I, Schafer ZT, Neamati N, Mancias JD, Koutmos M, Shah YM. Recharacterization of RSL3 reveals that the selenoproteome is a druggable target in colorectal cancer. bioRxiv [Preprint]. 2024 Apr 1:2024.03.29.587381. doi: 10.1101/2024.03.29.587381. PMID: 38617233; PMCID: PMC11014488.] reports on the possibility that RSL3 inhibits selenoprotein synthesis more broadly than previously reported and on investigating this found that PRDXs have a role in colon through an impact of RSL3 on thioredoxin reductases, a small family of selenoproteins.